Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Gemcitabine with Cetuximab or Erlotinib in Advanced Pancreatic Cancer
NCT00091026Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Jan 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, erlotinib in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Jul 2004; status: completed.
02
Drugs
KL-140erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00091026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091026.